Genomics

2bPrecise Genomic EHR Mentor and MMC to Present at AMIA 2021

2bPrecise

Leader in precision medicine solutions and multispecialty clinic customerto discuss the promise of genetic data at the point of care

2bPrecise, a leader in precision medicine solutions, will present on the value of pharmacogenomics (PGx) at the AMIA 2021 Clinical Informatics Conference. The company will be joined by longtime customer Murfreesboro Medical Clinic and SurgiCenter (MMC) for the virtual presentation, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care.” Together, 2bPrecise and MMC will explore ways health IT tools and PGx testing can improve medication safety, reduce adverse drug events and accelerate therapeutic value for patients.

“Pharmacogenomics, or how drugs interact with a patient’s genes, is incredibly valuable when it comes to determining the best medication for a patient,” said Dr. Joel Diamond, a practicing physician at Handelsman Family Practice in Pittsburgh, PA and chief medical officer at 2bPrecise. “Genetic profiles can eliminate trial-and-error prescribing by ensuring medications are safe and effective from the outset. As an organization on the forefront of precision medicine, we are thrilled to showcase at AMIA and share now MMC is leveraging our tools to better understand a patient’s genetic data and provide better care.”

Dr. Diamond and MMC Chief Medical Informatics Officer and President Dr. Nicholas Cote will draw from their successful implementations of PGx programs to explore the role IT plays in giving providers better insight into patients’ genetic data to help inform clinical decisions. The duo will also discuss the obstacles commonly encountered when initiating point-of-care precision medicine programs, lessons learned and best practices from implementing these programs within their own practices, and measurable outcomes the organizations have experienced.

“Leveraging genetic data to identify how patients will metabolize certain medications is a critical step in ensuring patients receive high-value care,” said Dr. Cote. “Powerful precision medicine solutions can give providers the necessary support to make care decisions with certainty. We look forward to presenting at AMIA and sharing our successes and real-world experiences with colleagues who might be considering similar programs.”

Drs. Diamond and Cote’s session, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care,” will take place virtually Thursday, May 20, 2021 from 1:00–2:00 PM ET.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

Related posts

Deep Genomics to Participate in Citi PCA

Business Wire

Contactile Raises US$2.5 Million to Accelerate Development

PR Newswire

Ultima Genomics signs development agreement with Regeneron

Phil Bowermaster